Suraksha Diagnostic Ltd

Suraksha Diagnostic Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has experienced a subtle shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend on weekly charts. Despite a recent upgrade in technical outlook, the company’s overall MarketsMOJO grade has been downgraded from Hold to Sell, reflecting cautious sentiment amid mixed indicator signals and modest price gains.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has experienced a subtle shift in its technical momentum, moving from a mildly bullish to a mildly bearish trend. Despite some positive weekly indicators, the overall technical landscape suggests caution for investors as the stock price declined by 1.45% on 2 June 2026, closing at ₹281.20.

Suraksha Diagnostic Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, reflecting a potential recalibration of investor sentiment amid evolving market dynamics. Despite a recent minor dip in share price, the company’s valuation metrics relative to peers and historical averages suggest a more compelling investment case within the healthcare services sector.

Suraksha Diagnostic Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 May 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the company’s current position as of 24 May 2026, providing investors with the latest insights into the stock’s performance and outlook.

Suraksha Diagnostic Ltd., a Kolkata-based healthcare services provider with a market capitalisation of ₹1,537 crores, reported consolidated net profit of ₹6.28 crores for Q4 FY26, marking a sharp decline of 16.49% quarter-on-quarter and 15.02% year-on-year. The results underscore mounting profitability challenges despite sustained revenue expansion, with the stock declining 4.05% following the announcement to close at ₹307.00 on May 22, 2026.

Suraksha Diagnostic Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its overall outlook. This change is driven by improvements in technical indicators, a reassessment of valuation metrics, steady financial trends despite recent challenges, and a stable quality profile. The micro-cap healthcare services company now carries a Mojo Score of 54.0, signalling a more balanced risk-reward profile for investors.

Suraksha Diagnostic Ltd, a micro-cap player in the healthcare services sector, has recently exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a day’s decline of 5.20%, the stock’s weekly and monthly technical indicators reveal a complex interplay of signals that investors should carefully analyse to gauge future price direction.

Suraksha Diagnostic Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest 2.21% gain on the day, the stock’s technical indicators present a complex picture, with some signals suggesting cautious optimism while others point to lingering weakness. This analysis delves into the recent price action, key technical indicators, and comparative returns to provide a comprehensive view for investors.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly indicators, the overall technical landscape suggests caution for investors as the stock navigates mixed signals from key momentum and trend-following indicators.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.42%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This article analyses these technical parameters in detail, placing them in the context of recent price action and broader market performance.

Suraksha Diagnostic Ltd, a micro-cap player in the Healthcare Services sector, has recently seen its valuation grade downgraded from attractive to fair, reflecting a notable shift in price attractiveness. With a current price of ₹284.65 and a price-to-earnings (P/E) ratio of 44.53, investors are reassessing the stock’s relative value amid evolving market dynamics and sector comparisons.

Suraksha Diagnostic Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Suraksha Diagnostic Ltd, a micro-cap player in the healthcare services sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change comes amid evolving price-to-earnings (P/E) and price-to-book value (P/BV) ratios, which now position the stock differently relative to its historical averages and peer group. Investors are advised to carefully analyse these valuation dynamics alongside the company’s operational metrics and market performance to gauge its price attractiveness.

Suraksha Diagnostic Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 April 2026, providing investors with the latest insights into the company’s performance and outlook.